ARK Diagnostics Introduces the ARK™ Zopiclone Assay for the Sensitive Detection of Zopiclone in Urine
Fremont, CA — ARK Diagnostics, Inc., is pleased to announce the launch of its ARK™ Zopiclone Assay, a homogeneous enzyme immunoassay designed for the detection of zopiclone in human urine.
Zopiclone, a non-benzodiazepine hypnotic commonly prescribed for the treatment of insomnia, has gained increasing attention in forensic and toxicology settings due to its potential for misuse. The ARK Zopiclone Assay provides a reliable and automated testing solution with a cutoff concentration of 10.0 ng/mL and exceptionally high cross-reactivity to eszopiclone (≥200%), enabling broader detection capabilities for related compounds.
Designed for use on a wide range of fully automated chemistry analyzers, the assay demonstrates consistent analytical performance making it ideal for high-throughput forensic and criminal justice laboratories seeking reliable, streamlined workflows.
The ARK™ Zopiclone Assay is available in the United States for Criminal Justice and Forensic Use Only.
About ARK Diagnostics
ARK Diagnostics, Inc. is a leading developer and manufacturer of high-quality in vitro diagnostic reagents for clinical laboratories worldwide. Headquartered in Fremont, California, ARK specializes in innovative homogeneous enzyme immunoassays designed for automated chemistry analyzers.
Contact Information
ARK Diagnostics, Inc.
48089 Fremont Blvd.
Fremont, California, 94538
877-869-2320
sales@ark-tdm.com
www.ark-tdm.com
To learn more about the ARK Zopiclone Assay, visit www.ark-tdm.com or email sales@ark-tdm.com
Zopiclone, a non-benzodiazepine hypnotic commonly prescribed for the treatment of insomnia, has gained increasing attention in forensic and toxicology settings due to its potential for misuse. The ARK Zopiclone Assay provides a reliable and automated testing solution with a cutoff concentration of 10.0 ng/mL and exceptionally high cross-reactivity to eszopiclone (≥200%), enabling broader detection capabilities for related compounds.
Designed for use on a wide range of fully automated chemistry analyzers, the assay demonstrates consistent analytical performance making it ideal for high-throughput forensic and criminal justice laboratories seeking reliable, streamlined workflows.
The ARK™ Zopiclone Assay is available in the United States for Criminal Justice and Forensic Use Only.
ARK Diagnostics, Inc. is a leading developer and manufacturer of high-quality in vitro diagnostic reagents for clinical laboratories worldwide. Headquartered in Fremont, California, ARK specializes in innovative homogeneous enzyme immunoassays designed for automated chemistry analyzers.
Contact Information
ARK Diagnostics, Inc.
48089 Fremont Blvd.
Fremont, California, 94538
877-869-2320
sales@ark-tdm.com
www.ark-tdm.com
To learn more about the ARK Zopiclone Assay, visit www.ark-tdm.com or email sales@ark-tdm.com
Category Press Releases